Skip to main content
. 2023 Sep 13;29(22):4596–4605. doi: 10.1158/1078-0432.CCR-23-1578

Figure 5.

Figure 5. In the absence of a baseline monitoring timepoint, ctDNA detection on chemoIO can inform subsequent outcomes on IO maintenance. Kaplan–Meier analysis depicting (A) PFS and (B) OS for all patients with an available C4 sample (including those with no baseline sample or negative baseline ctDNA levels). In multivariate analysis using a Cox model adjusting for clinical and genomic features, ctDNA positivity remains a statistically significant prognostic factor (Supplementary Fig. S6). IO, immunotherapy; OS, overall survival; PFS, progression-free survival.

In the absence of a baseline monitoring timepoint, ctDNA detection on chemoIO can inform subsequent outcomes on IO maintenance. Kaplan–Meier analysis depicting (A) PFS and (B) OS for all patients with an available C4 sample (including those with no baseline sample or negative baseline ctDNA levels). In multivariate analysis using a Cox model adjusting for clinical and genomic features, ctDNA positivity remains a statistically significant prognostic factor (Supplementary Fig. S6). IO, immunotherapy; OS, overall survival; PFS, progression-free survival.